Introduction {#s1}
============

Until the early 1990s, metered dose inhalers (MDIs) that contained chlorofluorocarbons (CFCs) as propellant were the most common way to administer inhaled therapy for asthma and chronic obstructive pulmonary disease (COPD). In 1987, the Montreal Protocol on Substances that Deplete the Ozone Layer included the phasing out of CFCs,[@R1] warranting the development of new ways to deliver inhaled therapy for asthma and COPD. This included dry-powder inhalers (DPIs), CFC-free MDIs that used hydrofluorocarbons (HFCs) as a propellant and, aqueous/soft mist inhalers.

Studies of prescription patterns in Europe have found large differences among countries in choice of inhalation device. A study published in 2011 concluded that approximately 90% of inhaled corticosteroid (ICS) devices used in Sweden were DPIs, whereas in the UK, approximately 80% were MDIs.[@R2]

Unlike CFCs, HFCs are not ozone-depleting substances but they are still greenhouse gases that have a high global warming potential (GWP). In 2017, the British Thoracic Society issued a statement to encourage prescribers and patients to consider switching pressurised MDIs to non-propellant devices because of this difference in environmental impact. This statement was recently updated.[@R3]

This study aimed to compare the environmental impact of DPI and MDI combinations using calculated carbon footprint data for two DPIs, Ellipta and Accuhaler, and one MDI, Evohaler. A secondary aim was to compare the inhaler-related carbon footprint impact between England and Sweden and the potential for reduction of annual carbon footprint (CO~2~e) in England if the pattern of inhalation devices chosen in England were to resemble that in Sweden.

Methods {#s2}
=======

The CO~2~e of average use of three ICS and long-acting β2-agonist combinations Relvar^\*^ Ellipta (fluticasone furorate/vilanterol) (DPI), Seretide^\*^ Accuhaler (fluticasone propionate/salmeterol) (DPI), Seretide Evohaler (MDI) and two short acting β2-agonists Ventolin^\*^ Accuhaler (salbutamol) (MDI), and Ventolin Evohaler (MDI) in asthma and COPD have been estimated based on individually produced carbon footprints by GlaxoSmithKline and certified by the Carbon Trust. This was achieved by taking into account the whole life cycle of the device: production of pharmaceutical ingredients and the final product, packaging of product, distribution and storage, use and disposal ([online supplementary file](#SP1){ref-type="supplementary-material"}).
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Data on the prescriptions dispensed of inhalation devices in England and Sweden in 2017 was collected. In England, the prescription cost analysis that included prescriptions of 49 994 877 inhalers from the National Health Service for 2017 was used,[@R4] and in Sweden the corresponding data including 4 771 689 inhalers were obtained from IQVIVA, Stockholm, Sweden. The annual CO~2~e for inhalation devices in England was estimated by assuming a carbon footprint for MDIs of 20 kg CO~2~e and a carbon footprint for DPIs of 1 kg CO~2~e per inhaler; these values were approximated from carbon footprint data calculated for GlaxoSmithKline devices ([online supplementary file](#SP1){ref-type="supplementary-material"}). The potential reduction in carbon footprint was estimated by recalculating what the carbon footprint of inhalers in England would be if MDIs and DPIs were prescribed in the same proportions as in Sweden.

Results {#s3}
=======

The Evohaler MDIs had 20--30 times larger carbon footprints than the Accuhaler and Elipta DPIs ([table 1](#T1){ref-type="table"}). This difference was mainly related to the use phase (treatment) and the end of life phase (disposal) when the propellant is released.

###### 

Contribution of phases in the life cycle of different inhaler devices to their individual carbon footprint (net kg CO~2~e/per pack) and annual carbon footprints of each device

  ------------------------------------------------------------------------------------------------
                                      RELVAR\    SERETIDE\    VENTOLIN\    SERETIDE\   VENTOLIN\
                                      ELLIPTA\   ACCUHALER\   ACCUHALER\   EVOHALER\   EVOHALER\
                                      92/22 µg   50/500 µg    200 µg       25/250 µg   100 µg
  ----------------------------------- ---------- ------------ ------------ ----------- -----------
  Active pharmaceutical ingredients   0.02       0.25         0.02         0.08        0.10

  Manufacturing                       0.73       0.46         0.42         2.12        1.11

  Distribution                        0.03       0.06         0.02         0.03        0.02

  User phase                          0.00       0.12         0.12         10.68       19.39

  End of life                         0.03       0.01         0.01         6.08        7.38

  Net kg CO~2~e/pack                  0.80       0.90         0.60         19.00       28.00

  Net kg CO~2~e/year                  9.5        11.0         7.3\*        234.0       205.0\*
  ------------------------------------------------------------------------------------------------

\*If using on average two doses per day.

The combination of Relvar Ellipta (9.5 kg CO~2~e) and Ventolin Accuhaler (7.3 kg CO~2~e) had an annual carbon footprint of 17 kg CO~2~e, while the corresponding value for using the combination Seretide Evohaler (234 kg CO~2~e) and Ventolin Evohaler (205 kg CO~2~e) was 439 kg CO~2~e ([figure 1](#F1){ref-type="fig"}).

![Annual carbon footprints (kg CO~2~e) for different combinations of Relvar, Seretide and Ventolin and annual footprint reduction of different actions\*. *​\**Wynes and Nicholas.[@R7]](thoraxjnl-2019-213744f01){#F1}

In England in 2017, 70% of all inhalers sold were MDI, whereas the corresponding figure for Sweden was 13%. The difference was largest for SABA: 94 versus 10% MDIs in England and Sweden respectively, while the corresponding difference for devices that contained ICS was 62 versus 14%.

If England had the same rates of MDI use as Sweden, 550 kt CO~2~e would be saved annually ([table 2](#T2){ref-type="table"}).

###### 

Proportion of MDI use in different classes and potential reduction in kilo tons (kt) of CO~2~e if changing the proportion of MDI use in the England to the level of Sweden

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
                       England: inhalers/year   England:\   Sweden: inhalers/year   Sweden:\   England:\              England:\
                                                % MDI                               % MDI      CO~2~e (kt) per year   potential annual reduction of CO~2~e (kt)
  -------------------- ------------------------ ----------- ----------------------- ---------- ---------------------- -------------------------------------------
  SABA                 21 931 511               94          1 477 692               10         414.00                 350.0

  LABA                 700 195                  65          377 415                 2          9.30                   8.4

  SAMA                 421 191                  100         No data                 100        8.40                   0

  ICS                  6 733 445                94          765 796                 15         127.00                 101.0

  ICS+LABA             14 075 067               47          1 719 428               13         140.00                 91.0

  LAMA and LAMA+LABA   6 549 448                0           428 732                 0          6.55                   0

  LAMA+LABA + ICS      5211                     99          2 626                   100        −0.10                  0

  Total                49 994 877               70          4 771 689               13         705.0                  550.0
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

Analysis uses 2017 community prescribing data from the NHS in England (<https://digital.nhs.uk/>) and assumes carbon footprint of MDI is 20 kg CO~2~e and DPI is 1 kg CO~2~e. SAMA not included in analysis, as no DPI SAMA alternative is available. Potential annual reduction shows the hypothetical carbon savings if England were to prescribe the same proportions of MDI as Sweden.

DPI, dry powder inhaler; ICS, inhaled corticosteroid; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonist; MDI, metered dose inhaler; SABA, short-acting β~2~-agonist; SAMA, short-acting muscarinic antagonist.

Discussion {#s4}
==========

Using Ellipta and Accuhaler DPIs instead of Evohaler MDIs resulted in an annual carbon footprint reduction equivalent to 422 kg CO~2~e per patient. Applying the Swedish DPI and MDI distribution to England would result in an estimated annual reduction of 550 kt CO~2~e annually.

The impact of HFCs from inhalers on overall greenhouse gas emissions can be viewed from many perspectives. Internationally, HFC release from MDIs in 2014 was equivalent to 0.013 gt CO~2~e, which was about 3% of global GWP-weighted CO~2~e emissions of HFCs.[@R5] HFCs are also used as refrigerants in refrigeration, air-conditioning and heat pump equipment (80%); as blowing agents for foams (11%); as solvents and in fire extinguishers (5%).[@R6] From an individual patient's perspective, a comparison of Ventolin and Seretide Evohalers with Relvar Ellipta and Ventolin Accuhaler could save 422 kg CO~2~e per year per patient. This is similar to the per capita carbon reductions obtained if changing from a meat-based to a plant-based diet.[@R7] This calculation was based on a usage of two doses SABA per day.[@R8] In patients that are very well controlled and therefore not using any SABA at all the difference was 234 kg CO~2~e per year.

We found a large difference between England and Sweden in the distribution of inhalation devices. This is in accordance with previous data.[@R2] The reason for this difference is not entirely clear but could be related to marketing strategies and prescribers' and patients' biases.[@R2] In England, the carbon footprint of the National Health Service (NHS) is ≈23 mt CO~2~e. Pharmaceuticals procurement is 16% of the footprint, one quarter of which comes from MDIs.[@R9] Other carbon footprint sources include building and energy and travel (4.6 and 2.8 mt CO~2~e, respectively). The predicted reduction of 550 kt CO~2~e annually that we calculated by applying the Swedish distribution of inhalation devices to the population in England thus corresponds to approximately 2.6% of the total carbon footprint for NHS England.[@R9] The main weakness of this analysis was that the analysis was limited to GlaxoSmithKline devices as accurate carbon footprint data were not available from other manufacturers.

Key considerations for inhaler selection include healthcare professional knowledge of all the devices; inhalation manoeuvre achieved; airway disease severity, patient's ability to use their device correctly and their personal preferences.[@R10] Thus the final choice of inhaler includes many factors, such as the fundamental efficacy of the molecules, patient-use factors, and the environmental burden. It should be noted that any change from an MDI to DPI device in clinical practice should be based on a clinical assessment and needs to be actively supported by appropriate programmes of education and assessment to ensure correct inhaler technique.

We conclude that Ellipta and Accuhaler DPIs have considerably lower carbon footprints than Evohaler MDIs, at both an individual and a national level. The lower carbon footprint of DPIs should be considered alongside other factors for patients who are able to use these devices effectively.
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